Global superbug response needs $5bn each year, experts predict

Efforts to tackle drug-resistant infections will require a global fund of at least $5 billion each year, researchers have projected. Experts in infectious diseases are calling for a World Bank Trust Fund to coordinate global action on this growing public health crisis. Growing resistance is leading to the emergence of superbugs that can cause life-threatening infections, such as MRSA or drug-resistant tuberculosis.

Researchers say that tackling the problem will require a coordinated global response and recommend introducing targets to reduce the number of drug-resistant infections over the next five years.

$5 billion is needed annually to develop global systems for monitoring resistance and to establish the framework needed to address the threat, experts add.

It could also be used to accelerate the development of new vaccines, diagnostics and treatments, as well as regulatory processes to ensure that current medicines are being used appropriately.

In addition to financial investment, the group proposes global limits on antibiotics use. In particular, use of antibiotics in agriculture to promote growth of farmed animals should be phased out worldwide, they argue.

Improving access to clean water, sanitation and public health infrastructure will help to curb the spread of disease and reduce the overall need for antibiotics, they say.

Researchers from the US Centre for Disease Dynamics, Economics and Policy, the University of Edinburgh, New York University and Fudan University in China outlined their proposals in the journal Science.

Their recommendations come ahead of a United Nations General Assembly meeting in September, where heads of state from around the world will discuss how best to preserve global access to effective medicines for infectious diseases.

Professor Mark Woolhouse, of the University of Edinburgh’s Centre for Immunity, Infection and Evolution, said: “Drug resistance knows no borders, as we have seen with the spread of superbugs around the world. It is crucial that nations come together with appropriate financing and governance to tackle this challenge together.”

Most Popular Now

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Pfizer and BioNTech advance COVID-19 vaccine strat…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a randomized, active-controlled, observer-blind, Phase 2 study to...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

Scientists develop new biomimetic formulation for …

Glioblastoma multiforme (GBM) is an aggressive brain cancer with a poor prognosis and few treatment options. New and effective approaches for GBM treatment are therefore ...

New needle-free nasal vaccine shows promise for CO…

New research shows that a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection. The findings were published in mB...